Metacrine Shares Rise 10% Following Scrapped Equillium Deal - MarketWatch

Retrieved on: 2022-12-24 09:58:44

Tags for this article:

Click the tags to see associated articles and topics

Metacrine Shares Rise 10% Following Scrapped Equillium Deal - MarketWatch. View article details on hiswai:

Excerpt

But the clinical-stage biotechnology company's recent partnership with Ono Pharmaceutical is expected to extend its cash runway into 2025, ...

Article found on: www.marketwatch.com